Dr. Matthew V Buck, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Dr. Matthew J Harris, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 80 Highland Street, Laconia, NH 03247 Phone: 603-524-3211 |
Richard Hughes, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Robert Evans, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Eric T Meyer, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Nancy Kressin, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
News Archive
A new technique for obtaining cancer cells from blood samples without contamination from blood cells has made it feasible to conduct detailed genetic analysis of cancer cells without the need for tumour biopsy.
Babatunde Osotimehin, executive director of the United Nations Population Fund (UNFPA) and under-secretary-general of the U.N., answers questions about his work from Forbes contributor Rahim Kanani in this interview excerpt.
Physician researchers with The Ohio State University College of Medicine at the Wexner Medical Center say increased levels of the hormone aldosterone, already associated with hypertension, can play a significant role in the development of diabetes, particularly among certain racial groups.
Electronic nicotine delivery systems (ENDS), or e-cigarettes, debuted in China in 2003 and have since become available globally, particularly through the Internet. While they resemble traditional tobacco cigarettes, they produce fewer toxins in the vapor for the smoker. Still, these novel products have unknown long-term health and addiction consequences, are of varying nicotine content and delivery, and may appeal to nonusers and youth. ENDS have been banned by health authorities in Canada and Australia.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago